- Home
- HAFC vs RIGL Comparison
HAFC vs RIGL Comparison
Compare HAFC & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HAFC | RIGL |
|---|---|---|
| Founded | 1982 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 972.5M | 884.9M |
| IPO Year | 2000 | 2000 |
Fundamental Metrics
Financial Performance| Metric | HAFC | RIGL |
|---|---|---|
| Price | $32.14 | $44.44 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $32.17 | ★ $45.67 |
| AVG Volume (30 Days) | 161.3K | ★ 217.9K |
| Earning Date | 04-21-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.75% | N/A |
| EPS Growth | 22.44 | ★ 1867.68 |
| EPS | ★ 1.54 | 1.32 |
| Revenue | $270,165,000.00 | ★ $294,282,000.00 |
| Revenue This Year | $18.65 | N/A |
| Revenue Next Year | $7.28 | $12.75 |
| P/E Ratio | ★ $20.73 | $35.79 |
| Revenue Growth | 15.28 | ★ 64.15 |
| 52 Week Low | $22.85 | $24.84 |
| 52 Week High | $33.50 | $52.24 |
Technical Indicators
Market Signals| Indicator | HAFC | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 56.13 | 50.75 |
| Support Level | $31.44 | $40.05 |
| Resistance Level | $32.70 | $49.50 |
| Average True Range (ATR) | 0.49 | 1.52 |
| MACD | 0.10 | -0.39 |
| Stochastic Oscillator | 87.23 | 7.89 |
Price Performance
Historical ComparisonAbout HAFC Hanmi Financial Corporation
Hanmi Financial Corp is a Los Angeles-based bank that caters to Korean-Americans and other multi-ethnic communities across California, Colorado, Georgia, Illinois, New Jersey, New York, Texas, Virginia, and Washington. The bank mainly focuses on small businesses and commercial and real estate loans. It also offers a variety of international finance and trade services and products, including letters of credit, import financing, and export financing. The Bank's revenues are derived from interest and fees on loans, interest, and dividends on the securities portfolio, service charges on deposit accounts, and sales of SBA loans.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.